U.S. Medical Equipment Stock News

Krystal Biotech (KRYS) is back in focus after the United Kingdom granted marketing authorization for VYJUVEK, the first genetic medicine approved there for dystrophic epidermolysis bullosa, with orphan status and potential 12-year exclusivity. See our latest analysis for Krystal Biotech. At a latest share price of US$299.45, Krystal Biotech has pulled back over the past week but still shows a 30 day share price return of 9.88% and a 1 year total shareholder return of 139.46% relating to...

Earlier in May 2026, the European Commission granted marketing authorization for Agios Pharmaceuticals’ PYRUKYND (mitapivat) to treat anemia in adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, making it the only approved medicine across all EU member states for this broad thalassemia population. This decision not only broadens PYRUKYND’s labeled use beyond pyruvate kinase deficiency but also deepens Agios’ footprint in rare hematologic diseases...

Karooooo (KARO) stock is in focus after the company reported 20% revenue growth, strong gains in subscription and annual recurring revenue, a very large jump in free cash flow, and a 20% dividend increase. See our latest analysis for Karooooo. At a share price of $47.58, Karooooo has gained 2.30% over the last day and 5.57% over the past 90 days, but the 1-year total shareholder return is still down 7.58%. This comes after strong revenue growth, higher dividends, and new earnings guidance, so...

Zenas BioPharma recently reported that the first subject has been dosed in a Phase 1 trial of ZB021, an oral small‑molecule IL-17AA/AF inhibitor being tested in healthy volunteers in China in partnership with InnoCare Pharma. This program targets a space where no oral IL-17 inhibitors are currently approved or in late-stage development globally, potentially offering a differentiated option for autoimmune and inflammatory diseases. Next, we’ll examine how advancing ZB021 into Phase 1,...

In its latest quarterly report, ESCO Technologies posted revenues of US$309.3 million, an increase of 33.5% year on year, but below analyst expectations by 3.4%, with adjusted operating income also missing estimates. Management emphasized strong order growth and broad-based revenue strength across Navy, aerospace, Test, and utilities markets, underscoring resilient demand despite the softer-than-expected quarter. With ESCO delivering strong year-on-year growth yet missing analyst...

Earlier this month, Artisan Partners Asset Management reported Q1 results that paired sizable equity outflows and near-term equity headwinds with ongoing growth in its credit and alternatives platforms, while outlining continued efforts in M&A, product development, and ETF capabilities. The earnings call emphasized how shifting asset mix and product innovation are becoming increasingly central to Artisan Partners’ effort to sustain earnings resilience despite pressure on traditional equity...

Ares Management (ARES) is in focus after partnering with The Scion Group in a joint venture to acquire a 12 property, 7,578 bed student housing portfolio for about US$910 million. See our latest analysis for Ares Management. The Ares Management share price has risen 8.6% over the past 90 days, including an 8.0% 30 day share price return, yet is still down 25.2% year to date, while the 5 year total shareholder return of 163.1% points to strong longer term performance momentum. If deals like...

Elevance Health (ELV) is back in focus after first quarter 2026 results showed adjusted EPS of $12.58, a 5.1% year-over-year increase, and management raised full year adjusted EPS guidance. See our latest analysis for Elevance Health. The first quarter numbers and guidance upgrade have coincided with stronger momentum in the stock, with a 14.5% 1 month share price return and 17.5% 3 month share price return, while the 3 year total shareholder return is still lower. If Elevance Health’s move...

Camtek stock snapshot after recent trading move Camtek (NasdaqGM:CAMT) has drawn fresh attention after a recent trading move, with the stock last closing at US$167.37. For context, the share price is down about 18% over the past month but up roughly 9% in the past 3 months. See our latest analysis for Camtek. Despite the 1 month share price return declining 17.6%, Camtek’s year to date share price return of 44.9% and a very large 1 year total shareholder return suggest longer term momentum...

Earlier this week, Nebius and Bloom Energy announced a long-term agreement for Bloom to deploy 328 MW of behind-the-meter fuel cell capacity to power Nebius’s AI data centers, with the deal potentially delivering up to US$2.60 billion in energy service fees over ten years. The partnership not only replaces the need for gas turbines at the first site but also showcases how Bloom’s modular, fast-to-deploy fuel cells can address grid bottlenecks as AI operators seek cleaner, high-performance...

In recent months, Alarm.com Holdings has reported slowing revenue growth, flat operating margins, and weaker billing trends, which together indicate softer underlying demand and rising competitive pressure in its markets. These billing and margin pressures matter because they touch the core of Alarm.com’s recurring software model, raising fresh questions about how effectively the company can convert its installed base and technology investments into sustained profitability over time. We’ll...

Dole (DOLE) is back in focus after its Q1 2026 update, which combined solid revenue growth, higher costs, fresh investment plans in automation and AI, and an active hunt for European bolt-on acquisitions. See our latest analysis for Dole. The stock has had a mixed run, with the share price down 8.67% over the past 90 days and 4.56% over the past month, while the 1 year total shareholder return is 5.65%. This suggests that recent momentum has cooled despite a modest longer term gain. If Dole’s...

On May 12, 2026, Akso Health Group’s audit committee dismissed Onestop Assurance PAC as its independent registered public accounting firm and appointed CHI-LLTC as the new auditor, effective immediately. This change in external auditor highlights a meaningful shift in Akso Health Group’s approach to financial oversight and corporate governance transparency. We will now examine how the shift from Onestop Assurance PAC to CHI-LLTC may influence Akso Health Group’s investment narrative. Invest...

BrightView earnings reaction and what it means for investors BrightView Holdings (BV) recently reported Q1 revenue growth of 6.1% year on year, topping analyst expectations by 8.9%, while adjusted operating income lagged estimates and full-year guidance came in weaker than peers. Even so, the stock has risen 5% since the release. This suggests that investors are currently putting more weight on the revenue outperformance than on the profitability shortfall or softer outlook. See our latest...

Earlier this month, Silgan Holdings Inc.’s Board of Directors declared a quarterly cash dividend of US$0.21 per share, payable on June 15, 2026 to shareholders of record on June 1, 2026. This dividend decision highlights management’s commitment to ongoing cash returns even as the company contends with high production costs and constrained free cash flow. Next, we’ll examine how maintaining this dividend amid tight margins could influence Silgan Holdings’ investment narrative and future...

Euronet Worldwide recently reported a strong first quarter, with US$1.01 billion in revenue exceeding analyst expectations and underscoring progress across its global payments and money transfer operations. At its May 20, 2026 Investor Day, the company outlined a shift toward a unified global payments platform emphasizing digital channels, shared technology, and increased capital allocation to buybacks and acquisitions. Now we will explore how Euronet’s digital-first repositioning and...

Recent performance snapshot Uniti Group (UNIT) has drawn fresh attention after a mixed run in the stock, with the price around $11.04 and recent returns ranging from a decline over the past month to gains over the past 3 months and year to date. See our latest analysis for Uniti Group. The share price has cooled in the past month, down 7.85%, but that comes after a strong 90 day share price return of 36.97% and a 3 year total shareholder return of 115.83%. This suggests momentum has been...

Earlier in 2026, SiteOne Landscape Supply held its annual meeting, where shareholders elected William W. Douglas III and Jeri L. Isbell to one-year board terms, ratified Deloitte & Touche LLP as auditor for the 2026 fiscal year, and approved the advisory vote on executive compensation. On the same day, SiteOne reported first-quarter 2026 results that included a net loss and revenue below expectations, a combination that sharpened investor attention on how effectively its growth and margin...

Kosmos Energy (KOS) recently reported record quarterly and daily production, updated its full year production growth outlook, and set a higher debt reduction target, drawing fresh attention to the stock’s risk and reward profile. See our latest analysis for Kosmos Energy. The stock’s recent 1-day and 7-day share price returns, down 2.9% and 6.2%, contrast with a 30-day share price return of 7.8% and a 90-day gain of 47.1%. The 239.4% year to date share price return and mixed longer term total...

CG Oncology recently reported positive first results from its Phase 2 CORE-008 Cohort CX trial, showing encouraging high-grade event-free survival, high complete response rates, and a favorable safety profile for intravesical cretostimogene grenadenorepvec plus gemcitabine in high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer, with data presented at the 2026 AUA meeting. An interesting aspect is that more than 80% of patients were treated in community practices,...

NVIDIA (NVDA) just reported record quarterly results, paired with a 25x dividend increase to US$0.25 per share and a new US$80b buyback. This puts capital returns and AI growth firmly in focus for shareholders. See our latest analysis for NVIDIA. Despite a slight pullback around the results, with the share price down 1.9% over the last day and 4.4% over the past week, NVIDIA still shows firm momentum, with a 30 day share price return of 3.4% and a 1 year total shareholder return of 64.1% on...

Norwegian Cruise Line Holdings recently reported first-quarter results that exceeded its own guidance and consensus estimates, outlined US$125 million in SG&A run-rate savings, and entered a cooperation agreement with activist investor Elliott Management that reshaped its board and governance oversight. At the same time, directors Jonathan Z. Cohen and Jose E. Cil purchased tens of thousands of shares on the open market, even as a law firm announced an investigation into potential...

In the past quarter, Hancock Whitney reported first-quarter 2026 adjusted earnings per share of US$1.52, ahead of expectations, as higher net interest income and modest loan growth helped offset a restructuring loss in its securities portfolio and a drop in non-interest income. Alongside these results, management outlined a 2026 outlook calling for modest growth in loans, deposits, and net interest income, while also filing a Form 144 for proposed insider share sales tied to 2020 stock...

The latest review by the independent Data Safety Monitoring Committee of EyePoint (EYPT) pivotal Phase 3 DURAVYU program kept both LUGANO and LUCIA trials on course, with interim masked data indicating a continued favorable safety profile. See our latest analysis for EyePoint. EyePoint’s recent safety update for DURAVYU comes after a sharp share price pullback this year, with the stock down 26.03% on a year to date share price return but still showing a 127.64% total shareholder return over...